Hypothalamic Obesity

BOSTON — September 22, 2026 Rhythm Pharmaceuticals announced that Health Canada has approved IMCIVREE® (setmelanotide) for weight management in...

BOSTON, August 24, 2026 Rhythm Pharmaceuticals, Inc. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted...

Monterey, California, August 10, 2026 Elevation Spine announced that the U.S. Food and Drug Administration (FDA) has granted 510(k)...

San Francisco, California, August 12, 2026 Tasman Therapeutics announced a multi-year strategic partnership with Osmind to support the development...

Boston, Massachusetts, August 11, 2026 Rhythm Pharmaceuticals announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA)...

BOSTON, MA, May 1, 2026 Rhythm Pharmaceuticals, Inc. announced that the European Commission has granted marketing authorization for IMCIVREE®...

Boston, March 26, 2026 In a significant advancement for rare disease therapeutics, Rhythm Pharmaceuticals has received a positive opinion...

BOSTON, March 19, 2026 Rhythm Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Imcivree (setmelanotide) for...